Recent developments
GLP-1 capacity and access
Novo Nordisk announced a €432 million investment in its Monksland facility in Athlone to expand oral GLP-1 manufacturing. Separately, it partnered with telehealth company Hims & Hers to supply FDA-approved semaglutide and end promotion of compounded alternatives. Competition in orals intensified as Lilly’s ACHIEVE-3 trial showed orforglipron outperforming oral semaglutide. Weight-management innovation broadened with Phase II ZUPREME-1 results for petrelintide and a Novo–Vivtex collaboration to develop next-generation oral biologic medicines.
Low-carbon intermediates and ESG
BASF introduced reduced product carbon footprint variants of BDO, THF, PolyTHF, and NMP from Ludwigshafen, following ISO 14067 with TÜV review; pharma users can lower Scope 3 without reformulation. On ESG performance, WuXi Biologics was listed in the S&P Global Sustainability Yearbook 2026, reflecting continued emphasis on sustainable biomanufacturing.
Portfolio realignments and licenses
SEQENS sold its Limoges Botanical Actives and IVD units to Solabia, sharpening focus on Pharmaceutical Solutions and Specialty Ingredients. CABB divested Jayhawk to Anupam Rasayan, pivoting toward Pharma and Life Science specialties. Deal activity expanded capabilities: GSK finalized the RAPT Therapeutics acquisition and Asahi Kasei agreed to acquire Aicuris. Early-stage pipelines advanced via Boehringer’s exclusive license from Sitryx and Asahi Kasei Pharma’s global license with Alchemedicine.
Approvals shaping demand
New approvals may influence biologics and small-molecule supply: the FDA cleared TECVAYLI plus DARZALEX FASPRO for earlier-line RRMM and granted accelerated approval to HERNEXEOS (zongertinib) for HER2-mutant NSCLC. Regulators advanced endocrine and antiviral markets via new pediatric indications for Sogroya and Japan’s review of bepirovirsen for chronic hepatitis B.
Late-stage pipeline signals
Pipeline breadth remained high: GSK licensed global linerixibat rights to Alfasigma as China granted priority review for PBC-related itch. Autoimmune readouts included obinutuzumab’s positive Phase III SLE results and nipocalimab’s FDA Fast Track. In oncology, Merck reported benefits across RCC, bladder, and ovarian studies, including KEYNOTE-B15 in MIBC.